MAPT and Alzheimer disease: Four neurochemical cerebrospinal fluid (CSF) biomarkers, Aβ1–42, Aβ1–40, Tau protein (tTau), and Tau phosphorylated at threonine 181 (pTau(181)), are currently used as core diagnostic markers for AD (Lewczuk et al., 2020).